Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trialsRemo Panaccione, David T. Rubin, Walter Reinisch et al.|The Lancet|2025Cited by 44
EFFICACY AND SAFETY OF GUSELKUMAB THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS OF THE GALAXI 2 & 3 PHASE 3 STUDIESRemo Panaccione, Bruce E. Sands, Silvio Danese et al.|Gastroenterology|2024Cited by 28